Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer

Ryuichi Suemitsu, Ichiro Yoshino, Makiko Tomiyasu, Seiichi Fukuyama, Tatsuro Okamoto, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


Purpose. In view of the increasing number of patients diagnosed with lung cancer every year worldwide, there is an urgent need for an effective screening marker to improve its early detection. Methods. We quantified the level of immunoreactive proteins for the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in the sera of 54 patients with non-small cell lung cancer (NSCLC) and 25 healthy control subjects, by using enzyme-linked immunosorbent assays with specific monoclonal antibodies. Results. The TIMP-1 level was significantly higher, and the TIMP-2 level was significantly lower in the patients with NSCLC than in the controls. Furthermore, both TIMP-1 and TIMP-2 were significantly higher in patients with squamous cell carcinoma than in those with adenocarcinoma. The TIMP-1 level in patients with stage III/IV disease was significantly higher than that in those with stage I/II disease. The TIMP-1/TIMP-2 ratio was significantly higher in the patients with NSCLC, and the receiver-operating characteristic curves analysis revealed that the TIMP-1/2 ratio, but not TIMP-1 or -2 alone, was a better screening marker for NSCLC than carcinoembryonic antigen (P < 0.0001). Patients with a high TIMP-1 value had significantly shorter disease-free survival (P = 0.0479), but those with a high TIMP-1/2 ratio did not. Conclusion. The TIMP-1/2 ratio may be a good screening marker of NSCLC; however, it was less effective than TIMP-1 as a prognostic factor.

Original languageEnglish
Pages (from-to)896-901
Number of pages6
JournalSurgery today
Issue number11
Publication statusPublished - Nov 2004

All Science Journal Classification (ASJC) codes

  • Surgery


Dive into the research topics of 'Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this